Company Quick10K Filing
Alector
S-1 2020-01-27 Public Filing
10-K 2019-12-31 Filed 2020-03-24
10-Q 2019-09-30 Filed 2019-11-12
10-Q 2019-06-30 Filed 2019-08-12
10-Q 2019-03-31 Filed 2019-05-13
S-1 2019-01-07 Public Filing
10-K 2018-12-31 Filed 2019-03-26
8-K 2020-03-20 Earnings, Officers, Exhibits
8-K 2020-03-05 Officers
8-K 2020-01-29 Enter Agreement, Other Events, Exhibits
8-K 2019-12-13 Regulation FD, Other Events, Exhibits
8-K 2019-12-11 Officers, Regulation FD, Exhibits
8-K 2019-11-12 Earnings, Exhibits
8-K 2019-08-12 Earnings, Exhibits
8-K 2019-08-09 Officers, Exhibits
8-K 2019-06-08 Officers
8-K 2019-05-13 Earnings, Exhibits
8-K 2019-05-10 Shareholder Vote
8-K 2019-03-21 Earnings, Officers, Regulation FD, Exhibits
8-K 2019-02-11 Amend Bylaw, Other Events, Exhibits

Alector Financials

ALEC Metrics, Comps, Filings

Quarterly | Annual

Business

Our mission is to develop therapies that empower the immune system to cure neurodegeneration.

Our Discovery Platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases. Our Discovery Platform focuses on:

- Target Selection. We identify mutations in genes that control the brain's immune system, which we believe are the root cause of neurodegeneration, employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations, and then engineer immune modulating antibodies to counteract the harmful consequences of these genetic mutations.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Sonic (SONC) 1,407 0% 12.1 13% 531 820 424 0 71 172 2,084
MiMedx Group (MDXG) 1,394 88% 25.0 20% 179 36 303 267 35 54 1,357
Ruhnn Holding (RUHN) 1,367 0% 689 781 0 0 0 0 1,263
Mitel Networks (MITL) 1,350 58% 10.5 -1% 1,455 1,053 1,304 752 -14 171 1,791
Toga (TOGL) 1,380 31% -72.5 -97% 20 9 13 4 -19 -19 1,367
Turning Point Therapeutics (TPTX) 1,323 -17.6 -12% 436 16 0 0 -51 -51 900
Medallia (MDLA) 3,513 63% -45.4 -13% 611 227 199 125 -78 -71 3,217
Engility (EGL) 1,300 0% 14.1 -2% 1,965 1,257 1,901 0 -34 156 2,197
web.com (WEB) 1,285 67% 12.5 3% 1,500 1,199 751 507 50 152 1,899
Gossamer Bio (GOSS) 1,048 -7.6 -27% 470 71 0 0 -126 -125 948
SuperValu (SVU) 1,258 8% 15.7 -0% 4,056 3,620 14,620 1,194 -19 168 2,645
Alector (ALEC) 1,035 0% -13.1 -17% 450 231 15 0 -75 -72 947
K2M Group Holdings (KTWO) 1,193 64% -36.8 -11% 422 192 281 181 -47 -31 1,137
KMG Chemicals (KMG) 1,185 42% 12.6 8% 818 402 466 198 65 117 1,473
Capella Education (CPLA) 1,175 0% 15.7 9% 287 59 443 0 27 67 1,057
State Bank Financial (STBZ) 1,168 8.1 1% 4,924 4,260 0 0 59 119 960
Healthcare Trust (HCT) 1,116 29% 20.4 -2% 2,331 1,194 372 108 -50 51 1,044
Cortexyme (CRTX) 662 -22.1 -18% 133 6 0 0 -25 -24 541
Apollo Education (APOL) 1,063 0% 5.9 -1% 1,955 886 2,000 0 -20 98 579
Enbridge Energy Management (EEQ) 1,062 -26.2 -3,288% 1 0 0 0 -26 -40 1,062

Balance Sheet ($MM)2019-03-312019-06-302019-09-30
Cash627188
Accounts Receivable
Inventory
PP&E243538
Assets496477450
Accounts Payable110
Long-Term Debt
Liabilities230232231
Stockholders' Equity266246219
Income Statement ($MM)2019-03-312019-06-302019-09-30
Revenue673
Cost of Revenue
Gross Profit
R&D212629
SG&A688
Tax
Net Income-19-25-32
Cash Flow ($MM)2019-03-312019-06-302019-09-30
Cash Operating-24-18-29
Cash Investing-1512646
Cash Financing170-01